China's COVID-19 surge might spawn a new coronavirus mutant
Could the COVID-19 surge in China unleash a new coronavirus mutant on the world?
Scientists do not know but worry that might happen, saying that it could be similar to Omicron variants circulating there now. It could also be a combination of strains, or something entirely different, they said.
“China has a population that is very large and there’s limited immunity. And that seems to be the setting in which we may see an explosion of a new variant," said Dr Stuart Campbell Ray, an infectious disease expert at Johns Hopkins University.
Every new infection offers a chance for the coronavirus to mutate, and the virus is spreading rapidly in China. The country of 1.4 billion has largely abandoned its zero-COVID policy.
Though overall reported vaccination rates are high, booster levels are lower, especially among older people. Domestic vaccines have also proven less effective against serious infections than Western-made mRNA versions. Many were given more than a year ago, which meant that immunity has waned.
The result? Fertile ground for the virus to change.
“When we’ve seen big waves of infection, it’s often followed by new variants being generated,” Ray said.
About three years ago, the original version of the coronavirus spread from China to the rest of the world and was eventually replaced by the Delta variant, followed by Omicron and its descendants, which continue plaguing the world today.
Dr Shan-Lu Liu, who studies viruses at Ohio State University, said many existing Omicron variants have been detected in China, including BF.7, which is extremely adept at evading immunity and is believed to be driving the current surge.
Experts said a partially immune population like China’s puts particular pressure on the virus to change. Ray compared the virus to a boxer that “learns to evade the skills that you have and adapt to get around those”.
One big unknown is whether a new variant will cause more severe diseases. Experts say there is no inherent biological reason the virus has to become milder over time.
“Much of the mildness we’ve experienced over the past six to 12 months in many parts of the world has been due to accumulated immunity either through vaccination or infection, not because the virus has changed in severity," Ray said.
In China, most people have never been exposed to the coronavirus. China's vaccines rely on an older technology producing fewer antibodies than mRNA vaccines.
Given those realities, Dr Gagandeep Kang, who studies viruses at the Christian Medical College in Vellore, India, said it remains to be seen if the virus will follow the same pattern of evolution in China as it has in the rest of the world after vaccines came out. “Or," she asked, “will the pattern of evolution be completely different?”
Recently, the World Health Organization expressed concern about reports of severe diseases in China. Around the cities of Baoding and Langfang outside Beijing, hospitals have run out of intensive care beds and staff as severe cases surge.
China plans to track the virus centres around three city hospitals in each province, where samples will be collected from walk-in patients who are very sick and those who die every week, Xu Wenbo of the Chinese Center for Disease Control and Prevention said at a briefing on Tuesday (Dec 20).
He said 50 of the 130 Omicron versions detected in China had resulted in outbreaks. The country is creating a national genetic database “to monitor in real time” how different strains were evolving and the potential implications for public health, he said.
At this point, however, there is limited information about genetic viral sequencing coming out of China, said Jeremy Luban, a virologist at the University of Massachusetts Medical School.
“We don’t know all of what’s going on,” Luban said. But clearly, "the pandemic is not over”.
BOOKMARK THIS: Our comprehensive coverage of the COVID-19 pandemic and its developments
Download our app or subscribe to our Telegram channel for the latest updates on the coronavirus pandemic: https://cna.asia/telegram